NCT00733551View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 23, 2008

Primary Completion Date

July 20, 2009

Study Completion Date

July 20, 2009

Conditions
Gastroparesis
Interventions
DRUG

GSK962040

GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.

DRUG

Placebo

Placebo tablets will be given orally, once daily, in the morning, in a fasted state.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00733551 - Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects. | Biotech Hunter | Biotech Hunter